Скачать или смотреть Dostarlimab + CP can be a new SOC for patients with primary A/R EC

Prof Matthew Powell speaks to ecancer about dostarlimab for primary advanced or recurrent endometrial cancer.

This study reported the outcomes by blinded independent central review (BICR) of the RUBY trial.

The RUBY trial evaluated the efficacy and safety of the anti–programmed death 1 (PD-1) dostarlimab with standard-of-care carboplatin-paclitaxel compared to carboplatin-paclitaxel alone in A/R EC. This study presents secondary efficacy endpoints by BICR.

The study found that there was a 71% reduction in progression or death in patients with defective mismatch repair cancers. Then the overall population of the study also showed statistically significant improvements as well as a very strong trend towards overall survival benefit with the addition of dostarlimab to carboplatin and paclitaxel.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php